US 12,269,861 B2
Chimeric ILT receptor compositions and methods
Joseph Henri Bayle, West University Place, TX (US); and MyLinh Thi Duong, Sugar Land, TX (US)
Assigned to NKILT Therapeutics, Inc., Springfield, NJ (US)
Filed by NKILT Therapeutics, Inc., Springfield, NJ (US)
Filed on Feb. 3, 2023, as Appl. No. 18/164,417.
Claims priority of provisional application 63/306,514, filed on Feb. 4, 2022.
Prior Publication US 2023/0348560 A1, Nov. 2, 2023
Int. Cl. A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 15/63 (2006.01)
CPC C07K 14/7051 (2013.01) [A61P 35/00 (2018.01); C12N 15/63 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 19 Claims
 
1. A chimeric receptor protein, comprising:
(a) a targeting region, that targets HLA-G, comprising an immunoglobulin-like transcript 4 (ILT4) D1-D2 extracellular domain that comprises an amino acid sequence that is 90% or more identical to SEQ ID NO: 57, wherein the targeting region lacks an ILT4 D3-D4 extracellular domain;
(b) a CD8α stalk domain;
(c) a CD8α transmembrane domain; and
(d) an intracellular domain (ICD), comprising:
(i) a signaling region capable of transducing a signal, upon binding of said targeting region to HLA-G, into the interior of an immune effector cell to elicit effector cell function, wherein the signaling region comprises a CD3ζ signaling domain; and
(ii) a costimulatory region comprising a 4-1BB costimulatory domain.